Uromigos
@Uromigos
Followers
7K
Following
534
Statuses
2K
The Uromigos strives to provide balanced, scientific content related to care of patients with GU malignancies. Click the link below to listen to our podcasts.
Worldwide
Joined February 2017
RT @tompowles1: Renal cancer highlights #ascoGU25. New HIF2a monotherapy (casdatifan) and combo (belzutifan/pembro) data. More KIM1 data,is…
0
15
0
🚨 Out now: Episode 384 features returning guest @Silke_Gillessen in a discussion on top studies to look forward to at @ASCO #GU25, such as new data from TALAPRO-2 and a trial investigating metastasis-directed therapy with standard therapy for oligometastatic castration-resistant prostate cancer. 🔵 Listen on GU Oncology Now: 🟢 Listen on Spotify: 🟣 Listen on Apple Podcasts:
0
9
18
⭐ In episode 383, we're joined by @BraunMDPhD of @YaleMed to discuss his recent paper on a personalized RCC vaccine that has demonstrated antitumor immunity and delayed recurrence. 🔵 Listen on GU Oncology Now: 🟢 Listen on Spotify: 🟣 Listen on Apple Music:
1
5
25
RT @tompowles1: Bladder cancer highlights #ASCOGU25 1) outcomes of pCR patients for gem/cis/durvalumab (NIAGARA) 2) neoadjuvant gem/cis/dur…
0
23
0
Listen to our podcast on this paper with @BraunMDPhD here:
1/ JUST IN: an 8 year #kidneycancer journey now published in @Nature: “A personalized neoantigen vaccine generates anti-tumor immunity in high-risk renal cell carcinoma”. A trial of #RCC vaccine, led together with first author @BraunMDPhD @YaleCancer and #PatrickOtt #DerinKeskin #CatherineWu @DanaFarber
@DanaFarber_GU @OncoAlert @DFCI_NeoVax
0
5
16
Check out our podcast with @BraunMDPhD on peptide and RNA cancer vaccines and his latest @nature @DrChoueiri paper
0
8
18
@BraunMDPhD from @YaleCancer joins us to discuss his @Nature paper of a personalized cancer vaccine in RCC patients.
0
3
12
🔊 Check out the new @uromigosjapan episode on the design and outcomes of the TROPiCS-04 study! 🟢 Listen on Spotify: 🟣 Listen on Apple Podcasts:
0
6
11
⭐ In our latest episode, Romain Banchereau of @genentech joins us to discuss and debate his recent @Cancer_Cell paper on molecular subtypes in urothelial cancer and implications for checkpoint blockade. 🔵 Listen on GU Oncology Now: 🟢 Listen on Spotify: 🟣 Listen on Apple Podcasts:
0
2
8
RT @Uromigos: Romain Banchereau joins us to discuss his @Cancer_Cell manuscript on molecular subtypes of urothelial cancer and implications…
0
12
0
Romain Banchereau joins us to discuss his @Cancer_Cell manuscript on molecular subtypes of urothelial cancer and implications for response to checkpoint inhibition.
1
12
42
RT @tompowles1: It was a fabulous meeting, discussing areas of uncertainly #AUC3. It’s going to be a busy year in bladder cancer. I hope we…
0
7
0
RT @tompowles1: When to rechallange with PD1 therapy in advanced RCC after progression on/after adjuvant pembro #AUC3 ? Rechallange studies…
0
16
0
RT @tompowles1: The muscle invasive bladder cancer session #AUC3 discussed perioperative durvalumab + ctDNA are changing the disease. Also,…
0
18
0
RT @tompowles1: All the renal cancer panel #AUC3 feel IMDC should not be used to select patients for 1st line ipi/nivo therapy. Guidlines…
0
11
0
RT @tompowles1: The #AUC3 meeting in Miami renal session. Voting on whom gets adjuvant pembrolizumab. Size (T stage) is unlikely to accurat…
0
8
0
RT @tompowles1: A personalised cancer RNA vaccine (cevumeran) +/- atezolizumab (n=210) in pretreated advanced tumors showed neoantigen spec…
0
27
0
⭐ Professor @_ShankarSiva of @PeterMacCC joins the show to discuss the emerging role of stereotactic body radiotherapy in primary and metastatic RCC tumors. 🔵 Listen on GU Oncology Now: 🟢 Listen on Spotify: 🟣 Listen on Apple Podcasts:
0
10
35